CE Disclosures and Faculty Information

• OVERVIEW OF ACTIVITY
  Lung cancer is the leading cause of cancer mortality in the United States for both men and women, resulting in more deaths than breast, prostate, colon and pancreatic cancer combined. Progress in the screening, prevention and treatment of this disease has been limited, and approximately 85% of patients who develop lung cancer will die of it. Traditional chemotherapy, surgery and radiation therapy have had a modest effect on long-term outcomes. However, the advent of biologic agents in lung cancer has led to recent improvements in disease-free and overall survival in select patient populations. Published results from ongoing and completed studies lead to the continual emergence of novel therapeutic strategies and changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing clinician must be well informed of these advances. Featuring information on the latest research developments along with expert perspectives, this CME program is designed to assist medical oncologists and radiation oncologists with the formulation of up-to-date clinical management strategies for the care of patients with lung cancer.
  
  LEARNING OBJECTIVES

  • Identify distinct subtypes of adenocarcinoma of the lung — including those with EGFR mutations, EML4-ALK gene fusions, ROS1 gene rearrangements and other recently identified driver mutations — and the approved and investigational treatment options for patients with these mutations.
  • Recall the scientific rationale for the ongoing investigation of novel agents or immunotherapeutic approaches in lung cancer, and counsel appropriately selected patients about study participation.
  • Employ an understanding of next-generation sequencing, and determine its clinical and/or research application for patients with metastatic lung cancer.
  • Describe mechanisms of tumor resistance to EGFR tyrosine kinase inhibitors, and identify investigational therapeutic opportunities to circumvent this process.
  • Develop an evidence-based approach to the selection of induction and maintenance biologic therapy and/or chemotherapy for patients with advanced non-small cell lung cancer.
  • Consider the use of multimodality therapy for appropriate patients with mesothelioma who may potentially be cured with this approach.

  ACCREDITATION STATEMENT
  
  CME credit is no longer available for this issue
  
  CREDIT DESIGNATION STATEMENT
  
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  This activity contains both audio and print components. The participant should listen to the audio MP3s and read the text portion. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.
  
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Camidge — Advisory Committee: ARIAD Pharmaceuticals Inc, Astex Pharmaceuticals, Clarient Inc, Exelixis Inc, Genentech BioOncology, ImmunoGen Inc, IndiPharm, Lilly, Servier; Contracted Research: ARIAD Pharmaceuticals Inc; Honoraria: ARIAD Pharmaceuticals Inc. Dr Langer — Advisory Committee: Abbott Laboratories, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clarient Inc, Clovis Oncology, Genentech BioOncology, Lilly, Merck, Myriad Genetics Inc, Roche Laboratories Inc; Consulting Agreements: Abbott Laboratories, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Lilly, Merck, Millennium: The Takeda Oncology Company, Roche Laboratories Inc; Contracted Research: Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Genentech BioOncology, GlaxoSmithKline, Lilly, Merck, Millennium: The Takeda Oncology Company, Pfizer Inc, Veridex LLC; Data Safety Monitoring Committee: Amgen Inc, Synta Pharmaceuticals Corp. Dr Tsao — Advisory Committee: Astellas, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Lilly, MedImmune Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, MedImmune Inc, Merck. Dr Rizvi — Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, Merck, Roche Laboratories Inc.
  
  EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Teva Oncology and VisionGate Inc.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Astellas, Biodesix Inc, Celgene Corporation, Genentech BioOncology, Lilly and Novartis Pharmaceuticals Corporation.
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
  Adobe Flash Player 10.2 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Last review date: December 2014
  Expiration date: December 2015